Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy

Colloids and Surfaces B: Biointerfaces

Volumn 152, Issue , 2017, Pages 296-301

  Rassu, Giovanna ^a   Soddu, Elena ^a   Posadino, Anna Maria ^a   Pintus, Gianfranco ^b   Sarmento, Bruno ^c,d   Giunchedi, Paolo ^a   Gavini, Elisabetta ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b Qatar University   (Qatar)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Chitosan; Nose to brain transport; RVG 9R cell penetrating peptide; siRNA; Solid lipid nanoparticle

Indexed keywords

CHITIN; CHITOSAN; COATINGS; FLAVORS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PEPTIDES; VIRUSES;

ALZHEIMER'S DISEASE; BRAIN TRANSPORT; CELL-PENETRATING PEPTIDE; COATING FORMULATIONS; SIRNA; SOLID LIPID NANOPARTICLE (SLN); SOLID LIPID NANOPARTICLES; TRANSCELLULAR PATHWAY;

GENE THERAPY;

BETA SECRETASE 1; CELL PENETRATING PEPTIDE; CHITOSAN; NANOCARRIER; SMALL INTERFERING RNA; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; DRUG CARRIER; NANOPARTICLE; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; BRAIN; BRAIN NERVE CELL; CACO-2 CELL LINE; CELL TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; EPITHELIUM; HUMAN; HUMAN CELL; MUCOADHESION; NANOENCAPSULATION; NONVIRAL GENE DELIVERY SYSTEM; NOSE; NOSE CAVITY; OLFACTORY NERVE; PROTEIN TRANSPORT; TRIGEMINAL NERVE; ZETA POTENTIAL; CHEMISTRY; GENETICS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CACO-2 CELLS; CELL-PENETRATING PEPTIDES; CHITOSAN; DRUG CARRIERS; HUMANS; NANOPARTICLES; NOSE; RNA, SMALL INTERFERING;

EID: 85010216510     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2017.01.031     Document Type: Article

References (41)

1. [1] Mistry, A., Stolnik, S., Illum, L., Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 379 (2009), 146–157.
2. [2] Lochhead, J.J., Thorne, R.G., Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64 (2012), 614–628.
3. [3] Pardeshi, C.V., Belgamwar, V.S., Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert Opin. Drug Deliv. 10 (2013), 957–972.
4. [4] Djupesland, P.G., Messina, J.C., Mahmoud, R.A., The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther. Deliv. 5 (2014), 709–733.
5. [5] Rassu, G., Soddu, E., Cossu, M., Gavini, E., Giunchedi, P., Dalpiaz, A., Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review. J. Drug Deliv. Sci. Technol. 32 (2016), 77–87.
6. [6] Illum, L., Nasal drug delivery-possibilities, problems and solutions. J. Control. Release 87 (2003), 187–198.
7. [7] Mistry, A., Stolnik, S., Illum, L., Nose-to-brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol. Pharm. 12 (2015), 2755–2766.
8. [8] Gavini, E., Rassu, G., Haukvik, T., Lanni, C., Racchi, M., Giunchedi, P., Mucoadhesive microspheres for nasal administration of cyclodextrins. J. Drug Target. 17 (2009), 168–179.
9. [9] Gavini, E., Rassu, G., Ferraro, L., Generosi, A., Rau, J.V., Brunetti, A., Giunchedi, P., Dalpiaz, A., Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres. J. Pharm. Sci. 100 (2011), 1488–1502.
10. [10] Gavini, E., Rassu, G., Ciarnelli, V., Spada, G., Cossu, M., Giunchedi, P., Mucoadhesive drug delivery systems for nose-to-brain targeting of dopamine. J. Nanoneurosci. 2 (2012), 47–55.
11. [11] Gavini, E., Rassu, G., Ferraro, L., Beggiato, S., Alhalaweh, A., Velaga, S., Marchetti, N., Bandiera, P., Giunchedi, P., Dalpiaz, A., Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting. Eur. J. Pharm. Biopharm. 83 (2013), 174–183.
12. [12] Dalpiaz, A., Fogagnolo, M., Ferraro, L., Capuzzo, A., Pavan, B., Rassu, G., Salis, A., Giunchedi, P., Gavini, E., Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antivir. Res. 123 (2015), 146–157.
13. [13] Rassu, G., Soddu, E., Cossu, M., Brundu, A., Cerri, G., Marchetti, N., Ferraro, L., Regan, R.F., Giunchedi, P., Gavini, E., Dalpiaz, A., Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J. Control. Release 201 (2015), 68–77.
14. [14] Yalcin, A., Soddu, E., Turunc Bayrakdar, E., Uyanikgil, Y., Kanit, L., Armagan, G., Rassu, G., Gavini, E., Giunchedi, P., Neuroprotective effects of engineered polymeric nasal microspheres containing hydroxypropyl-β-cyclodextrin on β-Amyloid (1–42)–induced toxicity. J. Pharm. Sci. 105 (2016), 2372–2380.
15. [15] Kim, I.D., Kim, S.W., Lee, J.K., Gene knockdown in the olfactory bulb, amygdala, and hypothalamus by intranasal siRNA administration. Korean J. Anat. 42 (2009), 285–292.
16. [16] Renner, D.B., Frey, W.H. II, Hanson, L.R., Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci. Lett. 513 (2012), 193–197.
17. [17] Kanazawa, T., Akiyama, F., Kakizaki, S., Takashima, Y., Seta, Y., Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 34 (2013), 9220–9226.
18. [18] Kanazawa, T., Morisaki, K., Suzuki, S., Takashima, Y., Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles. Mol. Pharm. 11 (2014), 1471–1478.
19. [19] Kim, I.-D., Sawicki, E., Lee, H.-K., Lee, E.-H., Park, H.J., Han, P.-L., Kim, K., Choi, H., Lee, J.-K., Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the post ischemic brain. Nanomedicine 12 (2016), 1219–1229.
20. [20] Orlacchio, A., Bernardi, G., Orlacchio, A., Martino, S., RNA interference as a tool for Alzheimer's disease therapy. Mini Rev. Med. Chem. 7 (2007), 1166–1176.
21. [21] Behlke, M.A., Progress towards in vivo use of siRNAs. Mol. Ther. 13 (2006), 644–670.
22. [22] Said Hassane, F., Saleh, A.F., Abes, R., Gait, M.J., Lebleu, B., Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci. 67 (2010), 715–726.
23. [23] Lin, T., Liu, E., He, H., Shin, M.C., Moon, C., Yang, V.C., Huang, Y., Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm. Sin. B 6 (2016), 352–358.
24. [24] Yadav, S., Gandham, S.K., Panicucci, R., Amiji, M.M., Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation. Nanomedicine 12 (2016), 987–1002.
25. [25] Zou, L.-L., Ma, J.-L., Wang, T., Yang, T.-B., Liu, C.-B., Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Curr. Neuropharmacol. 11 (2013), 197–208.
26. [26] Soddu, E., Rassu, G., Giunchedi, P., Sarmento, B., Gavini, E., From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery. Eur. J. Pharm. Sci. 74 (2015), 63–76.
27. [27] Alimohammadi, H., Silver, W.L., Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat. Chem. Senses 25 (2000), 61–66.
28. [28] Kozielski, K.L., Tzeng, S.Y., Green, J.J., Bioengineered nanoparticles for siRNA delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013), 449–468.
29. [29] Stockley, J.H., Ravid, R., O'Neill, C., Altered β-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. FEBS Lett. 580 (2006), 6550–6560.
30. [30] Fuentes, M.G., Torres, D., Alonso, M.J., Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B: Biointerfaces 27 (2003), 159–168.
31. [31] Zhang, N., Ping, Q., Huang, G., Xu, W., Cheng, Y., Han, X., Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327 (2006), 153–159.
32. [32] Soares, S., Fonte, P., Costa, A., Andrade, J., Seabra, V., Ferreira, D., Reis, S., Sarmento, B., Effect of freeze-drying, cryoprotectants and storage conditions on the stability of secondary structure of insulin-loaded solid lipid nanoparticles. Int. J. Pharm. 456 (2013), 370–381.
33. [33] Araújo, F., Shrestha, N., Shahbazi, M.-A., Fonte, P., Mäkilä, E.M., Salonen, J.J., Hirvonen, J.T., Granja, P.L., Santos, H.A., Sarmento, B., The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 35 (2014), 9199–9207.
34. [34] Mukherjee, T., Squillantea, E., Gillespieb, M., Shao, J., Transepithelial electrical resistance is not a reliable measurement of the Caco-2 monolayer integrity in Transwell. Drug Deliv. 11:Jan–Feb (1) (2004), 11–18.
35. [35] Kumar, P., Wu, H., McBride, J.L., Jung, K.-E., Kim, M.H., Davidson, B.L., Lee, S.K., Shankar, P., Manjunath, N., Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (2007), 39–43.
36. [36] Casettari, L., Illum, L., Chitosan in nasal delivery systems for therapeutic drugs. J. Control. Release 190 (2014), 189–200.
37. [37] Wiśniewska, M., The temperature effect on electro kinetic properties of the silica–polyvinyl alcohol (PVA) system. Colloid. Polym. Sci. 289 (2011), 341–344.
38. [38] Emami, J., Mohiti, H., Hamishehkar, H., Varshosaz, J., Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res. Pharm. Sci. 10 (2015), 17–33.
39. [39] Finger, T.E., St Jeor, V.L., Kinnamon, J.C., Silver, W.L., Ultrastructure of substance P-and CGRP immunoreactive nerve fibers in the nasal epithelium of rodents. J. Comp. Neurol. 294 (1990), 293–305.
40. [40] Müller, R.H., Mäder, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery−a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000), 161–177.
41. [41] Gartziandia, O., Egusquiaguirre, S.P., Bianco, J., Pedraz, J.L., Igartua, M., Hernandez, R.M., Préat, V., Beloqui, A., Nanoparticle transport across in vitro olfactory cell monolayers. Int. J. Pharm. 499 (2016), 81–89.